J Han van Krieken
Overview
Explore the profile of J Han van Krieken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
4393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young K, Shi W, Xu-Monette Z, Jia Y, Tzankov A, Go H, et al.
Res Sq
. 2025 Jan;
PMID: 39866884
Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive lymphoma with molecular heterogeneity not well characterize. In this study, we performed next-generation sequencing analysis for a large...
2.
Xu-Monette Z, Li Y, Snyder T, Yu T, Lu T, Tzankov A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4808-4821.
PMID: 37728879
Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma...
3.
van de Weerd S, Torang A, Zwager L, Koelink P, Koster J, Bastiaansen B, et al.
J Pathol
. 2023 Sep;
261(3):298-308.
PMID: 37681286
The consensus molecular subtype (CMS) classification divides colorectal cancer (CRC) into four distinct subtypes based on RNA expression profiles. The biological differences between CMSs are already present in CRC precursor...
4.
Li Y, Xu-Monette Z, Abramson J, Sohani A, Bhagat G, Tzankov A, et al.
Blood Adv
. 2022 Nov;
7(7):1308-1311.
PMID: 36399513
No abstract available.
5.
Albitar M, Zhang H, Goy A, Xu-Monette Z, Bhagat G, Visco C, et al.
Blood Cancer J
. 2022 Feb;
12(2):25.
PMID: 35105854
Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed...
6.
Xu-Monette Z, Wei L, Fang X, Au Q, Nunns H, Nagy M, et al.
Clin Cancer Res
. 2022 Jan;
28(5):972-983.
PMID: 34980601
Purpose: Diffuse large B-cell lymphoma (DLBCL) is molecularly and clinically heterogeneous, and can be subtyped according to genetic alterations, cell-of-origin, or microenvironmental signatures using high-throughput genomic data at the DNA...
7.
You H, Xu-Monette Z, Wei L, Nunns H, Nagy M, Bhagat G, et al.
Oncoimmunology
. 2021 Aug;
10(1):1928365.
PMID: 34350060
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors. In this study, we performed...
8.
Berendsen M, Stevens W, Brand M, van Krieken J, Scheijen B
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33260693
The majority of patients with diffuse large B-cell lymphoma (DLBCL) can be treated successfully with a combination of chemotherapy and the monoclonal anti-CD20 antibody rituximab. Nonetheless, approximately one-third of the...
9.
Deng M, Xu-Monette Z, Pham L, Wang X, Tzankov A, Fang X, et al.
Mol Cancer Res
. 2020 Nov;
19(2):249-260.
PMID: 33154093
Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with / double-hit (DH) represents a distinct entity with dismal prognosis after standard...
10.
Deng M, Zhang M, Xu-Monette Z, Pham L, Tzankov A, Visco C, et al.
J Hematol Oncol
. 2020 Nov;
13(1):148.
PMID: 33148342
The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and...